TY - JOUR T1 - <em>SOD1</em>, <em>ANG</em>, <em>VAPB</em>, <em>TARDBP</em>, and <em>FUS</em> mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlations JF - Journal of Medical Genetics JO - J Med Genet SP - 554 LP - 560 DO - 10.1136/jmg.2010.077180 VL - 47 IS - 8 AU - Stéphanie Millecamps AU - François Salachas AU - Cécile Cazeneuve AU - Paul Gordon AU - Bernard Bricka AU - Agnès Camuzat AU - Léna Guillot-Noël AU - Odile Russaouen AU - Gaëlle Bruneteau AU - Pierre-François Pradat AU - Nadine Le Forestier AU - Nadia Vandenberghe AU - Véronique Danel-Brunaud AU - Nathalie Guy AU - Christel Thauvin-Robinet AU - Lucette Lacomblez AU - Philippe Couratier AU - Didier Hannequin AU - Danielle Seilhean AU - Isabelle Le Ber AU - Philippe Corcia AU - William Camu AU - Alexis Brice AU - Guy Rouleau AU - Eric LeGuern AU - Vincent Meininger Y1 - 2010/08/01 UR - http://jmg.bmj.com/content/47/8/554.abstract N2 - Background Mutations in SOD1, ANG, VAPB, TARDBP and FUS genes have been identified in amyotrophic lateral sclerosis (ALS).Methods The relative contributions of the different mutations to ALS were estimated by systematically screening a cohort of 162 families enrolled in France and 500 controls (1000 chromosomes) using molecular analysis techniques and performing phenotype–genotype correlations.Results 31 pathogenic missense mutations were found in 36 patients (20 SOD1, 1 ANG, 1 VAPB, 7 TARDBP and 7 FUS). Surprisingly two FUS mutation carriers also harboured ANG variants. One family of Japanese origin with the P56S VAPB mutation was identified. Seven novel mutations (three in SOD1, two in TARDBP, two in FUS) were found. None of them was detected in controls. Segregation of detected mutations with the disease was confirmed in 11 families including five pedigrees carrying the novel mutations. Clinical comparison of SOD1, TARDBP, FUS and other familial ALS patients (with no mutation in the screened genes) revealed differences in site of onset (predominantly lower limbs for SOD1 and upper limbs for TARDBP mutations), age of onset (younger with FUS mutations), and in lifespan (shorter for FUS carriers). One third of SOD1 patients survived more than 7 years: these patients had earlier disease onset than those presenting with a more typical course. Differences were also observed among FUS mutations, with the R521H FUS mutation being associated with longer disease duration.Conclusions This study identifies new genetic associations with ALS and provides phenotype–genotype correlations with both previously reported and novel mutations. ER -